drugset / Trial / NCT05992935
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants (18 to 80 years of age).
Timeline
- Start
- 2023-08-25
- Primary completion
- 2026-09-22
- Completion
- 2026-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mRNA-1403 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | mRNA-1405 | Messenger RNA (mRNA) | — | — |